NEWTOWN, Pa., June 13, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage
biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a
primary focus on Myelodysplastic Syndromes (MDS), today announced that Dr. Ramesh Kumar, President & CEO, will present a corporate
overview at the BIO International Convention taking place June 19-22, 2017 in San Diego, CA.
Presentation Details:
Date: Tuesday, June 20, 2017
Time: 11:30 AM Pacific (2:30 PM, Eastern)
Location: San Diego Convention Center, Company Presentation Theater 4
A webcast of the presentation will be available on the Investor Page of Onconova’s website and will be active for 90 days following the event.
About Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small
molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). Rigosertib, Onconova's lead
candidate, is a proprietary Phase 3 small molecule agent, which we believe blocks cellular signaling by targeting RAS effector
pathways. Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against
specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three
product candidates in the clinical stage and several pre-clinical programs. Advanced clinical trials with the Company’s lead
compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS. For more information,
please visit http://www.onconova.com.
About IV Rigosertib
The intravenous form of rigosertib has been employed in Phase 1, 2, and 3 clinical trials involving more than 800 patients, and
is currently being evaluated in the randomized Phase 3 international INSPIRE trial for patients with higher-risk MDS, after failure
of hypomethylating agent, or HMA, therapy. This formulation is intended for patients with advanced disease, provides long duration
of exposure, and ensures dosing under a controlled setting.
About INSPIRE
The INternational Study of Phase III IV
RigosErtib, or INSPIRE, is based on guidance received from the U.S. Food and Drug Administration
and European Medicines Agency and derives from the findings of the ONTIME Phase 3 trial. INSPIRE is a multi-center, randomized
controlled study to assess the efficacy and safety of IV rigosertib in HR-MDS patients who had progressed on, failed to respond to,
or relapsed after previous treatment with an HMA within the first 9 months or nine cycles over the course of one year after
initiation of HMA treatment. This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring
treatment failure, as per NCCN Guidelines. The trial will enroll approximately 225 patients randomized at a 2:1 ratio into two
treatment arms: IV rigosertib plus Best Supportive Care versus Physician's Choice plus Best Supportive Care. The primary endpoint
of INSPIRE is overall survival and an interim analysis is anticipated. Full details of the INSPIRE trial, such as inclusion and
exclusion criteria, as well as secondary endpoints, can be found on clinicaltrials.gov (NCT02562443).
About Oral Rigosertib
The oral form of rigosertib was developed to provide more convenient dosing for use where the duration of treatment may extend
to multiple years. This dosage form also supports many combination therapy modalities. To date, 368 patients have been treated with
the oral formulation of rigosertib. Initial studies with single-agent oral rigosertib were conducted in hematological malignancies,
lower-risk MDS, and solid tumors. Combination therapy of oral rigosertib with azacitidine and chemoradiotherapy has also been
explored. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with
higher-risk MDS who require HMA therapy. A Phase 2 trial of the combination therapy has been fully enrolled and the preliminary
results were presented in 2016. This novel combination is the subject of an issued US patent with earliest expiration in 2028.
Forward Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of
1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act
of 1995, and involve risks and uncertainties. These statements relate to future events or Onconova Therapeutics, Inc.'s future
operations, clinical development of Onconova's product candidates and presentation of data with respect thereto, regulatory
approvals, expectations regarding the sufficiency of Onconova's cash and other resources to fund operating expenses and capital
expenditures, Onconova's anticipated milestones and future expectations and plans and prospects. Although Onconova believes that
the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have
been materially different from the results expressed or implied by such forward-looking statements. Onconova has attempted to
identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "intends,"
"may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes.
These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including Onconova's
ability to continue as a going concern, the need for additional financing and current plans and future needs to scale back
operations if adequate financing is not obtained, the success and timing of Onconova's clinical trials and regulatory approval of
protocols, and those discussed under the heading "Risk Factors" in Onconova's most recent Annual Report on Form 10-K and quarterly
reports on Form 10-Q.
Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update
any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect
the occurrence of unanticipated events.
GENERAL CONTACT: http://www.onconova.com/contact/ INVESTOR RELATIONS CONTACT: Lisa Sher, MBS Value Partners on behalf of Onconova Therapeutics Lisa.Sher@mbsvalue.com / (212) 750-5800
